霉酚酸酯在肾移植后肝功能不良患者中的应用

目的 分析和评价肾移植后肝功能不良患者使用霉酚酸酯（ＭＭＦ）的有效性和安全性。方法 １２例患者术后免疫抑制方案为：９例采用环孢素Ａ（ＣｓＡ）、硫唑嘌呤（Ａｚａ）、泼尼松（Ｐｒｅｄ）；３例采用ＣｓＡ、Ｐｒｅｄ。发生肝功能不良后，停用Ａｚａ；９例采用三联治疗的患者，６例减少ＣｓＡ和量１／４－１／３，３例改用ＣｓＡ、Ｐｒｅｄ；３例采用二联治疗者，１例减少ＣｓＡ，２例停用ＣｓＡ；１２例均加用ＭＭＦ１．５～

Application of MMF in renal transplant recipients with liver dysfunction

Objectives To analyze and evaluate the efficacy and safety of MMF in kidney transplant recipients with hepatic dysfunction. Methods Twelve liver dysfunction renal transplant recipients were treated with MMF ( 1.5 to 2.0 ?g/d). All patients discontinued Aza. Nine patients reduced cyclosporine A dose by 1/4 to 1/3.Liver function,rejection episodes and MMF adverse events were followed up for 6 months. Results By 6 months after using MMF, 11 of those patients got a normal liver function. No denova rejection episodes were observed during the six month. Conclusions MMF is a new potent immunosuppressive agent without hepatic or nephrotoxicity.In those liver dysfunction transplant recipients, the use of MMF can lead to Aza cessation and cyclosporine A reduction without increased rejection episode.